METHODS
A sample of 426 children with SPAA from the ANCHORS study was used to
calculate the Incremental Cost Effectiveness Ratio (ICER) for the
avoidance of Moderate to Severe Exacerbations (MSE), and also for the
improvement in childhood Asthma Control Test (c-ACT) or the Asthma
Control Questionnaire (ACQ5). We retrospectively collected data of
health encounters and drug consumption before and up to six years after
the beginning of the treatment with omalizumab.